Obstructive lung disease

Fifth Season Financial Offers Resources for COPD Patients Facing Financial Hardship

Wednesday, November 13, 2019 - 5:27pm

Recognizing National COPD Awareness Month this November, specialty lender Fifth Season Financial has developed an online resource for patients as well as a solution to help alleviate the financial strain associated with COPD and other advanced-stage illnesses.

Key Points: 
  • Recognizing National COPD Awareness Month this November, specialty lender Fifth Season Financial has developed an online resource for patients as well as a solution to help alleviate the financial strain associated with COPD and other advanced-stage illnesses.
  • Fifth Season Financial's new blog post, Financial Solutions for Patients with Chronic Obstructive Pulmonary Disease (COPD) , includes information on programs available to help minimize patients' financial challenges.
  • "Coping with a serious illness can drain savings and rack up bills swiftly," said Fifth Season Financial president Adam Balinsky.
  • Fifth Season has provided over $190 million in financial assistance to more than 600 patients across the United States.

Global Asthma Spacers Market 2019-2023 | Evolving Opportunities with ALLERGAN & Cipla | Technavio

Wednesday, November 13, 2019 - 11:30am

View the full release here: https://www.businesswire.com/news/home/20191113005363/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191113005363/en/
    Technavio has announced its latest market research report titled global asthma spacers market 2019-2023.
  • Also, the increase in online retail is anticipated to further boost the growth of the asthma spacers market.
  • The growing demand for respiratory care is expected to drive the growth of the global asthma spacers market.
  • Allergy, pollution, and smoking can result in several respiratory diseases such as obstructive airway diseases like asthma, COPD, and cystic fibrosis.

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

Tuesday, October 15, 2019 - 7:00am

LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.

Key Points: 
  • LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.
  • Kathleen Rickard, M.D., CMO at Verona Pharma, will expand on symptom data first announced by the Company on March 26, 2018 where ensifentrine produced clinically and statistically significant improvements in lung function as well as significant and progressive improvements in COPD symptoms.
  • Oral Presentation/Poster: Poster E1037 Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea
    COPD is a progressive and life-threatening respiratory disease without a cure.
  • Nebulized ensifentrine (RPL554) has shown significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in Verona Pharmas prior Phase 2 clinical studies in patients with moderate-to-severe COPD.

VIDA Partners With TeraRecon, Inc. For Distribution Of AI-Powered Lung Analysis

Monday, October 14, 2019 - 6:00pm

CORALVILLE, Iowa, Oct. 14, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing.

Key Points: 
  • CORALVILLE, Iowa, Oct. 14, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing.
  • By precisely quantifying lung characteristics in a chest CT scan, LungPrint helps providers detect COPD and other interstitial lung disease earlier, often when debilitating symptoms have yet to occur.
  • Early detection of chronic lung disease is reported to elongate life expectancies and reduce overall healthcare costs ( Larsson, et.
  • VIDA's LungPrint solution aims to provide greater precision and personalization across a range of lung diseases including lung cancer, obstructive airway diseases like emphysema and asthma, and interstitial lung disease.

Bayer, Brigham and Women's Hospital, Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases

Tuesday, September 24, 2019 - 10:00am

BERLIN and BOSTON, Sept. 24, 2019 /PRNewswire/ -- Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to research new drug candidates to treat chronic lung diseases.

Key Points: 
  • BERLIN and BOSTON, Sept. 24, 2019 /PRNewswire/ -- Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to research new drug candidates to treat chronic lung diseases.
  • Chronic lung disease is a broad term for a number of diseases of the airways and other structures of the lung, including chronic obstructive pulmonary disease (COPD).
  • "The joint lab concept continues to be an innovative model for collaboration between academia and industry, enabling novel approaches to drug discovery."
  • Bayer is researching a wide range of lung diseases, including interstitial lung disease, chronic obstructive pulmonary disease, pulmonary arterialhypertension, persistent chronic cough and obstructive sleep apnea.

KALY – Kali-Extracts Files Patent Application For CBD Formulation To Treat COPD Derived From Existing Kali-Extracts Patented Cannabis Extraction Process

Wednesday, August 21, 2019 - 2:20pm

The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the companys existing patented cannabis extraction process.

Key Points: 
  • The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the companys existing patented cannabis extraction process.
  • The company has also filed to register a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.
  • KALY plans to publish a website on Friday, August 23rd, dedicated to its new CBD formulation, RespRx, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.
  • The RespRx website to be published Friday will include details on KALYs recent patent and trademark applications for the RespRx CBD formulation.

KALY – Kali-Extracts Announces RespRx CBD Formulation For Symptoms Associated With COPD – A $14 Billion Market Opportunity

Tuesday, August 20, 2019 - 2:00pm

The update today highlights the companys CBD formulation for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.

Key Points: 
  • The update today highlights the companys CBD formulation for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.
  • The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the companys patented cannabis extraction process.
  • KALY also announces the filing of a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.
  • Accordingly, on behalf of the company, I have filed for a patent on the CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions.

U.S. News & World Report Names Blessing Hospital a High Performing Hospital for Two Chronic Conditions

Wednesday, August 14, 2019 - 8:00pm

WASHINGTON, Aug. 14, 2019 /PRNewswire-PRWeb/ -- Blessing Hospital has been recognized as a High Performing Hospital for 2019-20 by U.S. News & World Report.

Key Points: 
  • WASHINGTON, Aug. 14, 2019 /PRNewswire-PRWeb/ -- Blessing Hospital has been recognized as a High Performing Hospital for 2019-20 by U.S. News & World Report.
  • COPD is an umbrella term used to describe progressive lung diseases including emphysema, chronic bronchitis, and non-reversible asthma.
  • "CHF and COPD contribute to many hospitalizations in our region each year," said Maureen Kahn, RN, MHA, MSN, president/chief executive officer, Blessing Health System and Blessing Hospital.
  • "Blessing Hospital providers are committed to helping people manage these types of chronic conditions to help them stay out of the hospital and enjoy the highest quality of life possible."

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026 - ResearchAndMarkets.com

Tuesday, June 18, 2019 - 4:22pm

The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide.
  • COPD is characterized by diminished lung function, and is often accompanied by respiratory symptoms including chronic productive cough, wheezing, and dyspnea (shortness of breath).
  • Significant unmet need remains for novel therapies that prevent COPD disease progression in addition to providing symptomatic improvement.

Initial Study of the Minimally Invasive RheOx™ Device Demonstrates Positive Results for Chronic Bronchitis Patients

Thursday, May 23, 2019 - 12:00pm

The initial study evaluated the investigational use of RheOx in 33 patients with chronic bronchitis, a type of Chronic Obstructive Pulmonary Disease(COPD).

Key Points: 
  • The initial study evaluated the investigational use of RheOx in 33 patients with chronic bronchitis, a type of Chronic Obstructive Pulmonary Disease(COPD).
  • The device is designed to reduce cough and mucus production through a minimally invasive, bronchoscopicprocedure.
  • "More than 9 million Americans suffer from chronic bronchitis without a therapy to reduce excess mucus production.
  • RheOx is a bronchoscopic therapy designed to deliver non-thermal energy to the airways to reduce mucus-producing cells in patients with chronic bronchitis.